Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a canadian breast screening program: A nested case-control study

Clinical Breast Cancer

Volumn 11, Issue 1, 2011, Pages 27-32

  Rayson, Daniel ^a,e   Payne, Jennifer Isabelle ^a,b   Abdolell, Mohamed ^a,c   Barnes, Penny ^a   MacIntosh, Rebecca ^a   Foley, Theresa ^d   Younis, Tallal ^a   Burns, Ariel ^a   Caines, Judy ^a,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Nova Scotia Breast Screening Program   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clinical outcomes; Interval breast cancer; Pathology

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SCREENING; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL;

EID: 79953785015     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2011.n.005     Document Type: Article

References (36)

1. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. (review) Cochrane Database Syst Rev 2006; (Issue 4):CD001877.
2. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 54:141-69. (Pubitemid 36722306)
3. Shapiro S, Coleman E, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. Int J Epidemiol 1998; 27:735-42. (Pubitemid 28504958)
4. Report from the evaluation indicators working group: guidelines for monitoring breast screening program performance. Public Health Agency of Canada, Ottawa, Ont. Available at: http://www.phac-aspc.gc.ca/publicat/eiwg-gtie/app-c- eng.php. Accessed: May 18, 2009.
5. Rosenberg RD, Yankaskas BC, Abraham LA, et al. Performance benchmarks for screening mammography. Radiology 2006; 241:55-66. (Pubitemid 44433335)
6. Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Ann Oncol 2008; 19:614-22. (Pubitemid 351461029)
7. Organized breast screening programs in Canada: report on program performance in 2003 and 2004. Public Health Agency of Canada, Ottawa, Ont. Last modified, 7/1, 2008.
8. Bulliard JL, Sasieni P, Klabunde C, et al. Methodological issues in international comparison of interval breast cancers. Int J Cancer 2006; 119:1158-63. (Pubitemid 44116926)
9. Houssami N, Irwig L, Ciatto S. Radiological surveillance of interval breast cancers in screening programmes. Lancet Oncol 2006; 7:259-65. (Pubitemid 43286455)
10. Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168:98-104. (Pubitemid 351881896)
11. Lawrence G, Wallis M, Allgood P, et al. Population estimates of survival in women with screen- detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009; 16:179-85.
12. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen-detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14:1108-12. (Pubitemid 40656455)
13. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34. (Pubitemid 47219710)
14. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000; 92:743-9. (Pubitemid 30365535)
15. Hofvind S, Geller B, Skaane P. Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 2008; 49:975-81.
16. Collins S, Woodman CBJ, Threlfall A, et al. Survival rates from interval cancer in NHS breast screening programme. BMJ 1998; 316:832-3. (Pubitemid 28112432)
17. Vitak B, Stal O, Manson JC, et al. Interval cancers and cancers in non-attenders in the Ostergotland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 1997; 33:1453-60. (Pubitemid 27404905)
18. Burrell HC, Sibbering DM, Wilson ARM, et al. Screening interval breast cancers: mammographic features and prognostic factors. Radiology 1996; 199:811-7. (Pubitemid 26157489)
19. Wang H, Bjurstam N, Bjorndal H, et al. Interval cancers in the Norwegian breast screening program: frequency, characteristics and use of HRT. Int J Cancer 2001; 94:594-8.
20. Raja MAK, Hubbard A, Salman AR. Interval breast cancer: is it a different type of breast cancer? Breast 2001; 10:100-8. (Pubitemid 32390223)
21. Zackrisson S, Janzon L, Manjer J, et al. Improved survival rate for women with interval breast cancer- results from the breast screening programme in malmo, Sweden 1976-1999. J Med Screen 2007; 14:138-43. (Pubitemid 47511123)
22. Brekelmans CT, Peeters PH, Deurenberg JJ, et al. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 1995; 31A:1830-5.
23. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999; 91:2020-8.
24. Bordas P, Jonsson H, Nystrom L, et al. Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast 2007; 16:47-54. (Pubitemid 46172856)
25. Porter GJR, Evans AJ, Burrell HC, et al. Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 2006; 13:115-22. (Pubitemid 44452722)
26. Bare M, Bonfill X, Andreu X. Relationship between the method of detection and prognostic factors for breast cancer in a community with a screening programme. J Med Screen 2006; 13:183-91. (Pubitemid 46057726)
27. Nova Scotia Breast Screening Program Annual Report 2008 (2007 data). Nova Scotia Health, Halifax NS, 2008.
28. Hofvind S, Skaane P, Vitax B, et al. Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program. Radiology 2005; 237:437-43. (Pubitemid 41507877)
29. Ciatto S, Catarzi S, Lamberini MP, et al. Interval breast cancers in screening: the effect of mammography review method on classification. Breast 2007; 16:646-52. (Pubitemid 350154453)
30. Caines JS, Gallant J, Foley T, Payne JI. A review of interval breast cancers diagnosed among participants of a Canadian breast screening program (in preparation).
31. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45. (Pubitemid 350003059)
32. R development core team (2008). R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. ISBN 3-900051. Available at: http://www.R-project.org.
33. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784-92. (Pubitemid 41549890)
34. Cronin KA, Feuer EJ, Clarke LD, et al. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst Monogr 2006; 36:112-21.
35. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356:227-36. (Pubitemid 46143226)
36. Buist DS, Porter PL, Lehman C, et al. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 2004; 96:1432-40. (Pubitemid 39429667)